NZ628969A - Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme - Google Patents

Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme

Info

Publication number
NZ628969A
NZ628969A NZ628969A NZ62896913A NZ628969A NZ 628969 A NZ628969 A NZ 628969A NZ 628969 A NZ628969 A NZ 628969A NZ 62896913 A NZ62896913 A NZ 62896913A NZ 628969 A NZ628969 A NZ 628969A
Authority
NZ
New Zealand
Prior art keywords
pyrimidin
pyrazolo
methyl sulfamate
ylamino
dihydroxy
Prior art date
Application number
NZ628969A
Other languages
English (en)
Inventor
Roushan Afroze
Indu T Bharathan
Jeffrey P Ciavarri
Paul E Fleming
Jeffrey L Gaulin
Mario Girard
Steven P Langston
Francois R Soucy
Tzu-Tshin Wong
Yingchun Ye
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of NZ628969A publication Critical patent/NZ628969A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
NZ628969A 2012-02-17 2013-02-14 Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme NZ628969A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261600070P 2012-02-17 2012-02-17
PCT/US2013/026113 WO2013123169A1 (en) 2012-02-17 2013-02-14 Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme

Publications (1)

Publication Number Publication Date
NZ628969A true NZ628969A (en) 2017-03-31

Family

ID=48982730

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ628969A NZ628969A (en) 2012-02-17 2013-02-14 Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme

Country Status (30)

Country Link
US (4) US9290500B2 (https=)
EP (3) EP2814791A4 (https=)
JP (1) JP6122877B2 (https=)
KR (1) KR20140123104A (https=)
CN (1) CN104136399B (https=)
AR (1) AR092797A1 (https=)
BR (1) BR112014020365B1 (https=)
CA (1) CA2864672C (https=)
CL (1) CL2014002181A1 (https=)
CO (1) CO7071135A2 (https=)
CR (1) CR20140380A (https=)
DO (1) DOP2014000187A (https=)
EA (1) EA035020B1 (https=)
EC (1) ECSP14019113A (https=)
ES (1) ES2739150T3 (https=)
GE (1) GEP201706687B (https=)
HK (1) HK1201817A1 (https=)
IL (1) IL234016A0 (https=)
MA (1) MA35932B1 (https=)
MX (1) MX352963B (https=)
NZ (1) NZ628969A (https=)
PE (1) PE20142244A1 (https=)
PH (1) PH12014501832A1 (https=)
SG (2) SG10201606581RA (https=)
TN (1) TN2014000351A1 (https=)
TW (1) TWI593688B (https=)
UA (1) UA116534C2 (https=)
UY (1) UY34629A (https=)
WO (1) WO2013123169A1 (https=)
ZA (1) ZA201406103B (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8008307B2 (en) 2006-08-08 2011-08-30 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of E1 activating enzymes
EP2814791A4 (en) 2012-02-17 2015-08-19 Millennium Pharm Inc PYRAZOLOPYRIMIDINYL INHIBITORS OF ACTIVATION ENZYME OF UBIQUITIN
EP2879681A4 (en) 2012-08-03 2015-12-23 Millennium Pharm Inc INDOINDUBSTITUTED PYRROLOPYRIMIDINYL HIBITORS OF UBA6
JP6378759B2 (ja) 2013-07-02 2018-08-22 ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. Sumo活性化酵素阻害剤として有用なヘテロアリール化合物
SG11201610476VA (en) 2014-07-01 2017-01-27 Millennium Pharm Inc Heteroaryl compounds useful as inhibitors of sumo activating enzyme
JP6697453B2 (ja) * 2014-10-29 2020-05-20 ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. ユビキチン活性化酵素阻害物質及び放射線の投与
WO2016069392A1 (en) 2014-10-29 2016-05-06 Millennium Pharmaceuticals, Inc. Administration of ubiquitin-activating enzyme inhibitor and chemotherapeutic agents
AU2019370200B2 (en) 2018-10-30 2024-12-19 Kronos Bio, Inc. Compounds, compositions, and methods for modulating CDK9 activity
WO2022253188A1 (en) * 2021-05-31 2022-12-08 Impact Therapeutics (Shanghai) , Inc Nitrogen-containing fused heteroaromatic bicyclic compounds as usp1 inhibitors and the use thereof
WO2023021498A1 (en) * 2021-08-16 2023-02-23 Moya Bio Ltd. Fused azole and furan based nucleoside analogs and uses thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003073989A2 (en) 2002-02-28 2003-09-12 Biota, Inc. Nucleoside 5'-monophosphate mimics and their prodrugs
US7196092B2 (en) 2002-09-04 2007-03-27 Schering Corporation N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7563798B2 (en) 2002-09-04 2009-07-21 Schering Corporation Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
MY137843A (en) 2002-09-04 2009-03-31 Schering Corp Pyrazolopyrimidines as cyclin dependent kinase inhibitors
CA2497444C (en) 2002-09-04 2010-11-30 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
US20070179161A1 (en) 2003-03-31 2007-08-02 Vernalis (Cambridge) Limited. Pyrazolopyrimidine compounds and their use in medicine
JP2005008581A (ja) * 2003-06-20 2005-01-13 Kissei Pharmaceut Co Ltd 新規なピラゾロ[1,5−a]ピリミジン誘導体、それを含有する医薬組成物およびそれらの用途
US20050130974A1 (en) 2003-10-17 2005-06-16 Rigel Pharmaceuticals, Inc. Benzothiazole compositions and their use as ubiquitin ligase inhibitors
WO2006002284A1 (en) 2004-06-22 2006-01-05 Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors
RS52458B (sr) 2005-02-04 2013-02-28 Millennium Pharmaceuticals Inc. Inhibitori e1 aktivirajućih enzima
TWI333953B (en) 2005-10-06 2010-12-01 Schering Corp Pyrazolopyrimidines as protein kinase inhibitors
EA024006B1 (ru) 2006-02-02 2016-08-31 Миллениум Фармасьютикалз, Инк. Ингибиторы е1 активирующих ферментов
EP1992008A1 (en) * 2006-02-28 2008-11-19 Sez Ag Device and method for liquid treating disc-like articles
US8008307B2 (en) 2006-08-08 2011-08-30 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of E1 activating enzymes
ZA200900670B (en) * 2006-08-08 2010-04-28 Millennium Pharm Inc Heteroaryl compounds useful as inhititors of E1 activating enzymes
JP5539864B2 (ja) 2007-06-12 2014-07-02 アカオゲン,インコーポレーテッド 抗菌剤
EP2178880B1 (en) 2007-08-02 2017-10-04 Millennium Pharmaceuticals, Inc. Process for the synthesis of e1 activating enzyme inhibitors
US9216983B2 (en) 2007-12-21 2015-12-22 Board Of Regents, University Of Texas System Dihydroorotate dehydrogenase inhibitors with selective anti-malarial activity
WO2010086040A1 (en) 2009-01-29 2010-08-05 Biomarin Iga, Ltd. Pyrazolo-pyrimidines for treatment of duchenne muscular dystrophy
WO2010088518A2 (en) 2009-01-31 2010-08-05 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
EP2430026A1 (en) 2009-05-14 2012-03-21 Millennium Pharmaceuticals, Inc. Hydrochloride salt of ((1s,2s,4r)-4-{4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo [2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate
MX2012010115A (es) 2010-03-01 2013-02-26 Gtx Inc Compuestos para el tratamiento de cancer.
US20120077814A1 (en) 2010-09-10 2012-03-29 Zhong Wang Sulfonamide, sulfamate, and sulfamothioate derivatives
JP6038150B2 (ja) 2011-08-24 2016-12-07 ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. Nedd8活性化酵素阻害剤
EP2814791A4 (en) 2012-02-17 2015-08-19 Millennium Pharm Inc PYRAZOLOPYRIMIDINYL INHIBITORS OF ACTIVATION ENZYME OF UBIQUITIN
EP2879681A4 (en) 2012-08-03 2015-12-23 Millennium Pharm Inc INDOINDUBSTITUTED PYRROLOPYRIMIDINYL HIBITORS OF UBA6
JP6378759B2 (ja) 2013-07-02 2018-08-22 ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. Sumo活性化酵素阻害剤として有用なヘテロアリール化合物
SG11201610476VA (en) 2014-07-01 2017-01-27 Millennium Pharm Inc Heteroaryl compounds useful as inhibitors of sumo activating enzyme

Also Published As

Publication number Publication date
MX352963B (es) 2017-12-15
CO7071135A2 (es) 2014-09-30
DOP2014000187A (es) 2014-10-15
EP3173413A1 (en) 2017-05-31
CN104136399B (zh) 2018-08-07
JP6122877B2 (ja) 2017-04-26
ECSP14019113A (es) 2015-09-30
EP2814791A4 (en) 2015-08-19
CL2014002181A1 (es) 2014-12-12
EP3536692A1 (en) 2019-09-11
US9290500B2 (en) 2016-03-22
EA035020B1 (ru) 2020-04-17
AR092797A1 (es) 2015-05-06
MX2014009944A (es) 2014-11-10
SG10201606581RA (en) 2016-09-29
BR112014020365A2 (pt) 2020-12-22
TWI593688B (zh) 2017-08-01
BR112014020365B1 (pt) 2023-02-23
HK1201817A1 (en) 2015-09-11
PH12014501832A1 (en) 2014-11-17
JP2015508775A (ja) 2015-03-23
US20170217968A1 (en) 2017-08-03
EA201400831A1 (ru) 2014-12-30
ZA201406103B (en) 2017-11-29
WO2013123169A1 (en) 2013-08-22
US20130217682A1 (en) 2013-08-22
EP3536692B1 (en) 2021-04-07
GEP201706687B (en) 2017-06-26
PE20142244A1 (es) 2015-01-07
US20160244455A1 (en) 2016-08-25
EP3173413B1 (en) 2019-05-01
TW201345909A (zh) 2013-11-16
CR20140380A (es) 2014-10-28
EP2814791A1 (en) 2014-12-24
CN104136399A (zh) 2014-11-05
SG11201404757WA (en) 2014-09-26
CA2864672A1 (en) 2013-08-22
US9796725B2 (en) 2017-10-24
TN2014000351A1 (en) 2015-12-21
IL234016A0 (en) 2014-09-30
US9663525B2 (en) 2017-05-30
MA35932B1 (fr) 2014-12-01
CA2864672C (en) 2018-01-09
KR20140123104A (ko) 2014-10-21
UA116534C2 (uk) 2018-04-10
US20140088096A9 (en) 2014-03-27
UY34629A (es) 2013-09-02
US20170369499A1 (en) 2017-12-28
US10202389B2 (en) 2019-02-12
ES2739150T3 (es) 2020-01-29

Similar Documents

Publication Publication Date Title
NZ628969A (en) Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme
PH12018500106A1 (en) Ethynyl derivatives as metabotropic glutamate receptor modulators
PH12018550049A1 (en) Protein kinase inhibitor, preparation method and medical use thereof
JP2014051526A5 (https=)
EA201301319A1 (ru) Производные пиридин-2(1н)-она, применимые в качестве лекарственных средств для лечения миелопролиферативных нарушений, отторжения трансплантата, иммунологически обусловленных и воспалительных заболеваний
GEP20125621B (en) 3-aminocarbazole compound, pharmaceutical composition containing it and preparation method therefor
MX348920B (es) Derivados de 2-(fenil o pirid-3-il)aminopirimidina como moduladores de proteina cinasa 2 de repeticion rica en leucina (lrrk2) para el tratamiento de la enfermedad de parkinson.
NZ616298A (en) Aryl-or heteroaryl-substituted benzene compounds
PE20110575A1 (es) INHIBIDORES DE mTOR CINASA PARA INDICADORES DE ONCOLOGIA Y ENFERMEDADES ASOCIADAS CON LA TRAYECTORIA mTOR/PI3K/AKT
NZ578876A (en) 3-amino-pyrrolo[3,4-c]pyrazole-5 (1h, 4h, 6h) carbaldehyde derivatives as pkc inhibitors
MX2021013576A (es) Compuesto utilizado como inhibidor de la quinasa y aplicación del mismo.
AR080871A1 (es) Tieno[3,2-b]piridinas sustituidas como inhibidores de la actividad de la proteina tirosina quinasa
EA201391537A1 (ru) ЭТИНИЛЬНЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ПОЛОЖИТЕЛЬНЫХ АЛЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ mGluR5
PH12016500427A1 (en) Ethynyl derivatives
PH12012500867A1 (en) Ethynyl derivatives
PE20211776A1 (es) Derivados de 7-fenoxi-n-(3-azabiciclo[3.2.1]octan-8-il)-6,7-dihidro-5h-pirrolo[1,2-b][1,2,4]triazol-2-amina y compuestos relacionados como moduladores de gamma-secretasa para el tratamiento de la enfermedad de alzheimer
PH12013501572A1 (en) 5-(phenyl/pyridinyl-ethinyl)-2-pyridine/ 2-pyrimidine-carborxamides as mglur5 modulators
MX2021014319A (es) Metodo de sintesis del compuesto de furoimidazopiridina, forma de cristal del compuesto de furoimidazopiridina, y forma de cristal de la sal del mismo.
EA201691046A1 (ru) Производные этинилимидазолин-2,4-диона в качестве модуляторов метаботропного глутаматного рецептора 4 (mglur4)
PH12016501481A1 (en) Ethynyl derivatives
EA200800502A1 (ru) Соединения 3-аминокарбазола, фармацевтическая композиция, содержащая указанные соединения, и способ их получения
WO2008052088A8 (en) Chromane derivatives, synthesis thereof, and intermediates thereto
PH12015500496B1 (en) Ethynyl derivatives as modulators of mglur5 receptor activity
PH12015500261A1 (en) Arylethynyl pyrimidines
PE20150341A1 (es) Piperazino[1,2-a]indol-1-onas y [1,4]diazepino[1,2-a]indol-1-ona

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 14 FEB 2020 BY HENRY HUGHES IP LIMITED

Effective date: 20171009

LAPS Patent lapsed